Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Accumulated Expenses: 2010-2025

Historic Accumulated Expenses for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $10.2 million.

  • OptimizeRx's Accumulated Expenses rose 8351.63% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 8351.63%. This contributed to the annual value of $8.5 million for FY2024, which is 1012.2% up from last year.
  • As of Q3 2025, OptimizeRx's Accumulated Expenses stood at $10.2 million, which was up 8351.63% from $12.5 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Accumulated Expenses ranged from a high of $12.5 million in Q2 2025 and a low of $869791.0 during Q1 2021
  • Its 5-year average for Accumulated Expenses is $4.7 million, with a median of $2.9 million in 2021.
  • Per our database at Business Quant, OptimizeRx's Accumulated Expenses plummeted by 4805.6% in 2021 and then skyrocketed by 25318.13% in 2024.
  • OptimizeRx's Accumulated Expenses (Quarter) stood at $2.9 million in 2021, then fell by 10.39% to $2.6 million in 2022, then skyrocketed by 196.24% to $7.7 million in 2023, then increased by 10.12% to $8.5 million in 2024, then increased by 20.17% to $10.2 million in 2025.
  • Its last three reported values are $10.2 million in Q3 2025, $12.5 million for Q2 2025, and $9.3 million during Q1 2025.